Member Info for Doog58

The trouble is there are no profits in the short term and the nature of this type of situation is the share price will drift down.

The idea that it's one seller is laughable .
Sentiment has changed as uncertainty has increased.
I sold my last shares at 89 and got some stick but it was the rail delays which convinced me.
As I've said before markets don't like uncertainty.

The market will not like it as it doesn't like uncertainty.
A CFO stepping down especially with no replacement raises more questions than it answers.
Jumped or pushed?

I too am out for now.
I got in at 30 and its been my best share this year.
However I'm concerned with no news on the train in a company which usually communicates frequently.
I'm probably wrong but am currently risk adverse.
This is a very nice board and I wish you all well

In the short term the SP will drift down but medium to long a superb investment.
I'm holding

I increased my holding today but won't be losing any sleep.
Time for a beer.
Remember Art put a big chunk of his own money in recently.

Tony Bradbury is a proven turnaround specialist.
Copper is rising and will stay high for the foreseeable future.
Rambler is no longer a one trick pony with several streams on the go.
Gold assays are likely to be a bonus.
Large reserves once the mine is modernised.
These are my reasons for investing here.
I tend to ignore the noise and one poster is certainly a few bob short!

Just listened to AW's podcast.
I didn't realise he was once a stockbroker and sold on a successful business which shareholders did 'very well from'.
His comment that most mining companies are jam tomorrow, Ben's is jam today and soon to be caviar .(my words but his interpretation).
Another stand out was the economies of mine, wash plant, railway allowing very profitable margins.
Capex has been high and he will need a few months of production to free up the £35 million to pay the 10p original return of Capital to those clever enough to be in at the beginning .
Obviously all shareholders will get the dividend but I'll have to wait for 30p!
Worth listening to the bit about the conversion of the original £60M debt to royalty payments.
Very credible CEO who delivers what he promises.
I'm in from 30p on the tip of a customer!

There's no way AW would be doing the interview unless it was good news.
Bad news slips out in a low key Rns .

It's worth remembering that anyone can be anyone on this.
Regards
Elvis

The reason it's delayed is it's getting bigger and that takes more time to survey and assess.
Who was it who said something about patience?!

The worry for those still holding is that RG was the only substantial investor prepared to stump up cash at 0.1
He knows he can sell them down at a profit as new blood who don't know the history join in.
I would be very wary of any Riddler type ramping in the next few weeks .

Recurring revenues are the key.
Once the market catches on Deepverge will rerate.
Patience will be rewarded.

It could be used as a bargaining tool.
'We don't need Cuda as we've got all this but we'll take it off your hands if you insist '
I agree it's no coincidence it's been released now.

Gerry is right that what every business looks for is recurring revenues, which become cheaper and cheaper with scale and therefore more profitable.
Golfing analogy, Big order for show, recurring for dough!

I've added at what I believe will be a very cheap price in a years time.

I nearly sold out in December, so this is a very nice development.

I was recommended to Ben a few weeks ago and took a position on the Rns which is so far so good.
I'm thinking of trebling my position.
This bb seems very positive.
Any down sides?

I think Suzy knows its not the Rns people wanted regarding the funding. Its a very hard balancing act being a scientist and therefore very honest and a Ceo/ sales who needs to put a positive spin, hence the body language

I've been around Val for a long time and I don't want to add to the synchronised deramping which is obviously going on.
However why release an Rns saying we have nothing at present and why isn't a drug company willing to pay properly to fund the trials?